Tocilizumab biosimilar (AryoGen Pharmed)

托珠单抗生物类似药 (AryoGen Pharmed)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTocilizumab biosimilar (AryoGen Pharmed)

Drug Alias Name托珠单抗生物仿制药 (AryoGen Pharmed)托西利珠单抗生物仿制药 (AryoGen Pharmed)托西珠单抗生物仿制药 (AryoGen Pharmed)TEMZIVA

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionInterleukin-6 receptor alpha subunit antagonistsInterleukin-6 receptor subunit beta antagonists

TargetsInterleukin-6 receptor alpha subunitInterleukin-6 receptor subunit beta

Therapy Area/IndicationsArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesAryogen Biopharma

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsArthritis, Rheumatoid

Inactive IndicationsN/A

ATC CodeL04AC07